XML 83 R61.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration and Profit-Sharing Agreements - Beam Therapeutics (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2020
May 31, 2018
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Realized gain on corporate equity securities $ 16,400                   $ 16,366    
Collaboration and other research and development revenues     $ 11,419 $ 62,841 $ 10,749 $ 5,723 $ 12,284 $ 3,848 $ 2,330 $ 2,069 $ 90,732 $ 20,531 $ 31,937
Revenue type                     us-gaap:ServiceMember us-gaap:ServiceMember us-gaap:ServiceMember
Beam Therapeutics, Inc | License Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Non-cash consideration aggregate fair value received   $ 3,600                      
Contract termination notice   90 days                      
Total transaction price                       $ 3,800  
Collaboration and other research and development revenues                     $ 200 $ 200  
Revenue type                     us-gaap:ServiceMember us-gaap:ServiceMember  
Beam Therapeutics, Inc | License Agreement | Other income (expense)                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Realized gain on corporate equity securities                     $ 16,400